{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-025553","form_type":"8-K","ticker":"SNWV","cik":"0001417663","company_name":"SANUWAVE Health, Inc.","filed_at":"2026-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.256732+00:00","generated_at":"2026-05-15T05:45:59.374636+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sanuwave Health reports preliminary Q1 2026 revenue of $9.6-$9.7M, up 3-4% YoY","bullets":["Revenue expected $9.6M-$9.7M, 3-4% increase vs Q1 2025, within prior guidance.","CEO notes several large deals slid out of Q1, impacting the lower end of guidance.","Wound care market facing reimbursement changes for skin substitutes, causing pause.","High interest at SAWC conference; CEO says they are leaning in, not pulling back.","Preliminary results subject to adjustment after completion of quarter-end close."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-025553","json":"https://secwatch.observer/filing/0001628280-26-025553.json","markdown":"https://secwatch.observer/filing/0001628280-26-025553.md","text":"https://secwatch.observer/filing/0001628280-26-025553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417663/000162828026025553/0001628280-26-025553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417663/000162828026025553/snwv-20260416.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:45:59.374636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02a8ae2c01338b978f887c15b49222da7928b8f5","claim":"SANUWAVE Health, Inc. reported first quarter ended March 31, 2026 results: revenue $9.6 million to $9.7 million. Guidance reaffirmed.","evidence_excerpt":"Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417663/000162828026025553/0001628280-26-025553-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$9.6 million to $9.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}